ImmunityBio (IBRX) AI Stock Analysis

• Market Cap: $2.40B
• Dividend Yield: N/A
• Average Volume (3M): 9.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: 10238.41%
• EPS Growth: 47.67%
• Country: US
• Employees: 671
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 882,620,400
• 10 Day Avg. Volume: 6,731,622
• 30 Day Avg. Volume: 9,019,174
• PEG Ratio: -0.41
• Price to Book (P/B): -4.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.43
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 55.21
• Enterprise Value/Gross Profit: 111.55
• Enterprise Value/Ebitda: -2.30
• 1Y Price Target: $6.33
• Price Target Upside: 132.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: $3.00 ▲(10.29%Upside)

ImmunityBio's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage, persistent losses, and negative cash flows. The technical analysis provides a neutral outlook with no strong momentum signals. Valuation remains a concern due to unprofitability. However, the recent financing event is a positive factor, enhancing liquidity and supporting strategic initiatives.

Positive Factors

Market Adoption

ANKTIVA’s commercial launch marked a good start, underpinned by the implementation of a permanent J-code that streamlined reimbursement and accelerated adoption across urology practices.

Regulatory Approval

Regulatory milestones like RMAT designation and Expanded Access authorization recognize the urgent need to address immune collapse in hard-to-treat cancers, accelerating development and access to ImmunityBio's novel immunorestorative approach.

Negative Factors

Regulatory Challenges

ImmunityBio received a Refusal to File letter from the FDA for their sBLA for Anktiva in BCG unresponsive NMIBC for papillary disease.

Regulatory Uncertainty

The RTF letter introduces regulatory uncertainty, despite the identical treatment protocol between CIS and papillary cohorts.

ImmunityBio Business Overview & Revenue Model

Company Description

ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies that harness the power of the immune system to treat cancer and infectious diseases. Operating primarily in the biotechnology and pharmaceuticals sectors, the company focuses on developing and commercializing a diverse portfolio of immunotherapy products, including cell therapies, antibody therapies, and vaccines, aimed at providing long-term, durable responses in patients.

How the Company Makes Money

ImmunityBio generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of products developed using ImmunityBio's proprietary technologies. Additionally, the company may secure funding and grants from governmental and non-governmental organizations to support its research and development activities. As a clinical-stage company, ImmunityBio does not yet derive significant revenue from product sales, as its therapies are still in various stages of clinical trials and regulatory approval processes.

ImmunityBio Financial Statement Overview

Summary

ImmunityBio is facing significant financial challenges, with persistent losses, high leverage, and negative cash flows. While there is some revenue growth, the company remains heavily reliant on external financing to sustain operations. The negative equity and cash flow deficits highlight the need for improved operational efficiency and financial management to ensure long-term viability.

Income Statement

ImmunityBio has shown some revenue growth in the latest year, with revenue increasing from $622,000 to $14.7 million. However, the company has been consistently unprofitable, with negative net profit margins and EBIT margins over the years. The gross profit margin remains positive, but the high levels of operating losses and negative EBITDA indicate significant profitability challenges.

Balance Sheet

The company's balance sheet shows high leverage, with total liabilities exceeding total assets, resulting in negative stockholders' equity. This poses a risk for financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, and the negative return on equity further highlights profitability issues.

Cash Flow

ImmunityBio's cash flow statement reflects substantial operating cash flow deficits, which have worsened over the years. The free cash flow remains negative, indicating ongoing challenges in generating cash from operations. Although the company has raised financing in previous years, the consistent negative free cash flow poses a risk to sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.00K	14.74M	622.00K	240.00K	934.00K	605.00K
Gross Profit	47.00K	-2.81M	622.00K	-23.95M	934.00K	-8.54M
EBITDA	-86.74M	-241.76M	-436.18M	-335.51M	-315.38M	-187.93M
Net Income	-96.23M	-413.56M	-583.20M	-417.32M	-349.85M	-224.19M
Balance Sheet
Total Assets	208.26M	382.93M	504.45M	362.36M	468.91M	221.38M
Cash, Cash Equivalents and Short-Term Investments	98.55M	149.81M	266.46M	107.18M	317.12M	96.06M
Total Debt	15.78M	504.17M	726.72M	723.77M	645.66M	275.55M
Total Liabilities	40.45M	871.06M	1.09B	812.18M	712.82M	339.87M
Stockholders Equity	167.81M	-488.13M	-586.99M	-447.33M	-242.17M	-119.81M
Cash Flow
Free Cash Flow	-76.48M	-398.12M	-397.34M	-436.90M	-307.98M	-173.39M
Operating Cash Flow	-63.38M	-391.24M	-366.76M	-337.51M	-274.42M	-171.72M
Investing Cash Flow	57.10M	-12.25M	-30.47M	27.30M	-84.89M	-19.81M
Financing Cash Flow	-771.00K	281.63M	558.34M	233.61M	505.44M	150.68M

ImmunityBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.72
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 2.92, above the 50-day MA of 2.68, and below the 200-day MA of 3.31, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 47.23 is Neutral, neither overbought nor oversold. The STOCH value of 35.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRX.

ImmunityBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRSP	64 Neutral	$4.51B	―	-19.71%	―	-86.13%	-67.29%
Sector *	63 Neutral	CHF22.60B	15.13	10.81%	2.13%	47.85%	-11.82%
AMRX	63 Neutral	$2.64B	―	106.97%	―	13.42%	92.50%
IBRX	48 Neutral	$2.40B	―	78.99%	―	10238.41%	47.67%
IMVT	45 Neutral	$2.90B	―	-62.46%	―	―	-43.10%
MLTX	41 Neutral	$3.14B	―	-30.57%	―	―	-147.80%
EWTX	40 Underperform	$1.37B	―	-30.29%	―	―	7.97%

ImmunityBio Corporate Events

ImmunityBio Approves 2025 Equity Incentive Plan

On June 18, 2025, ImmunityBio, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity Incentive Plan was approved, replacing the 2015 Plan. This strategic move aims to better compete for and motivate key talent through equity-based awards, aligning the interests of employees and stockholders. Additionally, eight directors were re-elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for 2025 was ratified.

The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

ImmunityBio Secures $75 Million in Direct Offering

On April 7, 2025, ImmunityBio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering, involving the sale of 29,024,768 shares of common stock and warrants for additional shares. This transaction is expected to generate approximately $75 million in gross proceeds, supporting the company’s ongoing business operations. The offering is anticipated to close around April 9, 2025, subject to customary conditions, and could potentially yield an additional $90 million if the warrants are fully exercised. This financing move is part of ImmunityBio’s strategy to bolster its working capital and further its development of cancer vaccines and immunotherapies.